On February 10, “drug king” Wuxi Apptec Co.Ltd(603259) beat “Ning king” and ranked first on the hot search list. Today, Wuxi Apptec Co.Ltd(603259) A shares fell 7.41% to close at 85.86 yuan, with a cumulative decline of more than 20% in three days. What attracts people’s attention is also the after hours dragon and tiger list data, especially the selling list. In addition to the special seats for Shanghai Stock connect, the other four seats are special seats for institutions.
“Institutional selling is really unblinking.” Some investors joked that.
On the 10th, Wuxi Apptec Co.Ltd(603259) announced that neither the company nor its subsidiaries had been included in the “unconfirmed list” by the U.S. Department of Commerce. According to the company’s self-examination, as of the disclosure date of this announcement, the company has not found any other media reports or market rumors that need to be clarified or responded.
institutions sold a net 2.296 billion yuan
According to today’s data released by the dragon and tiger list, the total net sales of institutions were Wuxi Apptec Co.Ltd(603259) 2.296 billion yuan, of which 1.43 billion yuan was sold for only one institutional seat. According to Wuxi Apptec Co.Ltd(603259) today’s average price of 87.09 yuan, about 16.4 million shares were sold.
Looking at the three-day trading data of the dragon and tiger list, from February 8 to February 10, the total net sales of institutions were Wuxi Apptec Co.Ltd(603259) 1.271 billion; The Shanghai Stock connect bought 1.519 billion yuan, sold 2.161 billion yuan and sold 642 million yuan net. Obviously, whoever has heavy positions is most likely to sell. So which institutions have heavy positions Wuxi Apptec Co.Ltd(603259) ? The answer is the fund.
According to the shareholding data of the fund’s four seasons report, the top five positions are: 65.71 million shares of China EU medical and health mixed positions under Glenn; Liu Yanchun’s Jingshun Great Wall emerging growth mixed position of 30 million shares; Huaxia Shanghai Stock Exchange 50ETF index fund holds 17.5 million shares; ICBC Frontier Medical stock a holds 17 million shares; Yinhua rich theme fund holds 15 million shares.
has been on the dragon and tiger list for many times in recent months
Previously, Wuxi Apptec Co.Ltd(603259) has been on the dragon and tiger list for many times.
On February 8, Wuxi Apptec Co.Ltd(603259) fell to the limit. Dragon and tiger list data show that the special seats of Shanghai Stock connect bought 169 million yuan and sold 628 million yuan; The four institutions bought 574 million yuan of seats and sold 655 million yuan; Among them, the number of institutional seats sold by the second seller sold 215 million of the shares.
On December 15, 2021, Wuxi Apptec Co.Ltd(603259) fell by the limit and sold only one seat in the top five institutions. The listed institution sold 334 million yuan of Wuxi Apptec Co.Ltd(603259) shares.
Within three months, Wuxi Apptec Co.Ltd(603259) was sold by institutions with a net amount of 3.264 billion yuan.
Looking back at the information of Wuxi Apptec Co.Ltd(603259) appearing on the dragon and tiger list four times, it is not difficult to find that there are more and more institutional seats for large-scale trading, and the sales volume of institutions has repeatedly set a new record. Who on earth is selling Wuxi Apptec Co.Ltd(603259) ? According to the disclosure of the fund’s four seasons report, the above-mentioned public funds have such a shareholding volume. Market participants speculate that among these funds, Gelan and Liu Yanchun’s funds, which hold the largest number of shares, have the greatest probability.
US Department of Commerce list doubt
Mentioning Wuxi Apptec Co.Ltd(603259) , which fell on the hot search twice this week, we have to mention that Yaoming biological subsidiary was included in the “unverified list” by the U.S. Department of Commerce.
On February 7, some media reported that the official website of the US Department of Commerce included 33 Chinese entities in the “unverified list”, including two subsidiaries of YaoMing biology in Shanghai and Wuxi.
On February 8, Wuxi Apptec Co.Ltd(603259) A shares fell by the limit and Hong Kong shares fell by 11%; The trading of its drug Ming biology was suspended, once down 22.77%.
On the same day, Wuxi Apptec Co.Ltd(603259) announced that neither the company nor its subsidiaries were listed in UVL by the U.S. Department of Commerce. The current production and operation of the company is normal. The company has noticed media reports that two subsidiaries of YaoMing biology have been included in the list. Yaoming biology is an independent listed company, and the company does not hold any shares of YaoMing biology.
In addition, Yaoming biological also announced that it was actively taking temporary measures to remove its subsidiaries from the unverified list.
foreign institutions are still optimistic about
Although the involvement was included in the “unverified list” by the U.S. Department of Commerce, foreign institutions are still optimistic about Yaoming biology.
JPMorgan research report pointed out that the reason why Yaoming biological subsidiary of the US Department of Commerce was included in the unverified list (UVL) was that the Department of Commerce was unable to conduct on-site verification on the actual use of bioreactor hardware and high-efficiency hollow fiber filters purchased by the company from us suppliers, and Yaoming biological obtained the export approval of these products in the past 10 years, However, the Ministry of Commerce cancelled the on-site inspection originally scheduled for the end of 2019 and rescheduled it to 2020.
Damo believes that the impact of this list on its operation and finance is controllable in the short term, and Yaoming biological’s supplier diversification strategy seems to have foresight, and there is also a way to appeal. In view of the recent prosperity of YaoMing biology, Damo reiterated its target price of HK $112 and its “overweight” rating.
Credit Suisse Research Report maintained the “outperforming” rating of YaoMing biology, but the target price was reduced by 20.5% from HK $151 to HK $120, lowered the revenue growth forecast after 2022, and slightly increased the capital expenditure and operating expenditure in the medium term.
